| Identification | Back Directory | [Name]
4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole | [CAS]
931314-31-7 | [Synonyms]
4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole | [Molecular Formula]
C21H25N3O4S | [MDL Number]
MFCD14774311 | [MOL File]
931314-31-7.mol | [Molecular Weight]
415.51 |
| Chemical Properties | Back Directory | [Boiling point ]
612.6±65.0 °C(Predicted) | [density ]
1.22±0.1 g/cm3(Predicted) | [solubility ]
Chloroform: 10 mg/ml | [form ]
A solid | [pka]
-7.17±0.70(Predicted) | [color ]
Off-white to pink |
| Hazard Information | Back Directory | [Biological Activity]
SPA70 is a pregnane X receptor (PXR) antagonist (IC50 = 0.51 μM).1 It is selective for PXR over 10 additional nuclear receptors at concentrations greater than 5 μM, as well as over a panel of 384 kinases at 10 μM. SPA70 (0.1-10 μM) inhibits PXR activation induced by rifampicin in HEK293 cells expressing the human receptor. It also inhibits rifampicin-induced activity of the PXR target cytochrome P450 (CYP) isoform 3A4 (CYP3A4) in primary human hepatocytes. SPA70 (200 mg/kg) inhibits PXR agonist-induced CYP3A4-mediated metabolism of midazolam and paclitaxel in human PXR transgenic (hPXR-tg) mice. | [References]
1.Lin, W., Wang, Y.-M., Chai, S.C., et al.SPA70 is a potent antagonist of human pregnane X receptorNat. Commun.8(1)741(2017)
|
|
| Company Name: |
Key Organics Ltd.
|
| Tel: |
+44 (0) 1840-212137 |
| Website: |
www.keyorganics.net |
|